Cover Image
市場調查報告書

慢性咳嗽漱的開發中產品分析

Chronic Cough - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 288829
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
慢性咳嗽漱的開發中產品分析 Chronic Cough - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 61 Pages
簡介

慢性咳嗽是指成人連續八星期以上,兒童持續四星期以上的咳嗽。主要的症狀·前兆有鼻塞,聲音嘶啞,喘鳴聲·呼吸急促,胃灼熱,嘴巴內部發酸等。主要的治療藥有抗組織胺藥物和充血緩和劑,抗生素,鎮咳劑等。

本報告提供全球各國治療慢性咳嗽漱之開發中產品的開發情形相關分析,提供您產品開發·上市的最新趨勢,臨床實驗的各階段產品一覽,並彙整主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

慢性咳嗽漱概要

治療藥的開發

  • 慢性咳嗽漱開發中產品:概要
  • 慢性咳嗽漱開發中產品:比較分析

各企業開發中的慢性咳嗽漱治療藥

大學/研究機關研究中的慢性咳嗽漱治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

慢性咳嗽漱治療藥:開發中的產品一覽(各企業)

慢性咳嗽漱治療藥的開發企業

  • Afferent Pharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Vectura Group plc

慢性咳嗽漱:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • AF-219
  • cromolyn sodium
  • GRC-17536
  • GSK-2339345
  • VR-611 - Drug Profile

慢性咳嗽漱治療藥:開發中產品的最新趨勢

慢性咳嗽漱治療藥:開發暫停的產品

慢性咳嗽漱治療藥:開發中止的產品

慢性咳嗽漱相關產品的的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8503IDB

Summary

Global Markets Direct's, 'Chronic Cough - Pipeline Review, H2 2016', provides an overview of the Chronic Cough pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Cough and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Cough
  • The report reviews pipeline therapeutics for Chronic Cough by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Chronic Cough therapeutics and enlists all their major and minor projects
  • The report assesses Chronic Cough therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Chronic Cough

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chronic Cough
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chronic Cough pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chronic Cough Overview
  • Therapeutics Development
    • Pipeline Products for Chronic Cough - Overview
    • Pipeline Products for Chronic Cough - Comparative Analysis
  • Chronic Cough - Therapeutics under Development by Companies
  • Chronic Cough - Therapeutics under Investigation by Universities/Institutes
  • Chronic Cough - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Chronic Cough - Products under Development by Companies
  • Chronic Cough - Products under Investigation by Universities/Institutes
  • Chronic Cough - Companies Involved in Therapeutics Development
    • Afferent Pharmaceuticals, Inc.
    • AstraZeneca Plc
    • Conrig Pharma ApS
    • GlaxoSmithKline Plc
    • Glenmark Pharmaceuticals Ltd.
    • GW Pharmaceuticals Plc
    • NeRRe Therapeutics Ltd
    • Patara Pharma, Inc.
    • Pila Pharma AB
  • Chronic Cough - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AF-219 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cromolyn sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GRC-17536 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2339345 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lesogaberan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NEO-5937 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • orvepitant maleate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-1226 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize CB1 and CB2 for Chronic Cough and Inflammatory Skin Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XEND-0501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chronic Cough - Dormant Projects
  • Chronic Cough - Discontinued Products
  • Chronic Cough - Product Development Milestones
    • Featured News & Press Releases
      • Sep 07, 2016: Patara Pharma Announces Positive Phase 2 Results for the Treatment of Refractory Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis
      • May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference
      • May 03, 2016: Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors
      • Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial
      • Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet
      • Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company's Lead P2X3 Antagonist, AF-219
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chronic Cough, H2 2016
  • Number of Products under Development for Chronic Cough - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Chronic Cough - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016
  • Chronic Cough - Pipeline by AstraZeneca Plc, H2 2016
  • Chronic Cough - Pipeline by Conrig Pharma ApS, H2 2016
  • Chronic Cough - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Chronic Cough - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
  • Chronic Cough - Pipeline by GW Pharmaceuticals Plc, H2 2016
  • Chronic Cough - Pipeline by NeRRe Therapeutics Ltd, H2 2016
  • Chronic Cough - Pipeline by Patara Pharma, Inc., H2 2016
  • Chronic Cough - Pipeline by Pila Pharma AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Chronic Cough - Dormant Projects, H2 2016
  • Chronic Cough - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Chronic Cough, H2 2016
  • Number of Products under Development for Chronic Cough - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top